Jazz Pharmaceuticals JAZZ

HealthcareMarket cap $15B1 connection

Jazz Pharmaceuticals makes Xyrem/Lumryz for narcolepsy (a sleeping disorder affecting 200,000+ Americans), Epidiolex (the first FDA-approved cannabis-derived drug, for epilepsy), and oncology drugs. Its specialty pharmaceutical model targets underserved diseases where pricing power is high and generics are limited.

Open Jazz Pharmaceuticals's Company Hub Simulate a merger Supply chain See it on the map

Partners 1

Strategic partnerships, joint products and alliances

Johnson & JohnsonHealthcare · $654BJazz narcolepsy drug competing with J&J pipeline

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Jazz Pharmaceuticals's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=JAZZ" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Jazz Pharmaceuticals on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.